Susan L Rossell Selected Research

Body Dysmorphic Disorders (Body Dysmorphic Disorder)

12/2021	Cross-diagnostic cognitive heterogeneity in body dysmorphic disorder and obsessive-compulsive disorder.
12/2021	Is the needle as risky as the knife? The prevalence and risks of body dysmorphic disorder in women undertaking minor cosmetic procedures.
1/2021	An update on gender differences in major symptom phenomenology among adults with body dysmorphic disorder.
1/2021	Body dysmorphic disorder: a treatment synthesis and consensus on behalf of the International College of Obsessive-Compulsive Spectrum Disorders and the Obsessive Compulsive and Related Disorders Network of the European College of Neuropsychopharmacology.
1/2021	Childhood maltreatment and trauma is common and severe in body dysmorphic disorder.
10/2020	Examining memory performance in body dysmorphic disorder (BDD): A comparison study with obsessive compulsive disorder (OCD).
1/2020	Delusional themes in Body Dysmorphic Disorder (BDD): Comparisons with psychotic disorders and non-clinical Controls.
1/2019	Intranasal oxytocin alters amygdala-temporal resting-state functional connectivity in body dysmorphic disorder: A double-blind placebo-controlled randomized trial.
1/2019	Impaired Recognition of Negative Facial Emotions in Body Dysmorphic Disorder.
11/2018	The relationship between body dysmorphic disorder and obsessive-compulsive disorder: A systematic review of direct comparative studies.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Susan L Rossell Research Topics

Disease

34	Schizophrenia (Dementia Praecox) 12/2022 - 02/2006
27	Body Dysmorphic Disorders (Body Dysmorphic Disorder) 12/2021 - 01/2006
10	Obsessive-Compulsive Disorder (Disorder, Obsessive-Compulsive) 01/2022 - 01/2013
8	Psychotic Disorders (Schizoaffective Disorder) 03/2021 - 04/2015
5	Bipolar Disorder (Manic Depressive Psychosis) 02/2022 - 01/2020
5	Cognitive Dysfunction 12/2021 - 02/2006
3	Anorexia Nervosa 01/2022 - 11/2019
2	Wounds and Injuries (Trauma) 01/2021 - 01/2021
2	Neurobehavioral Manifestations 02/2020 - 08/2015
1	Substance-Related Disorders (Drug Abuse) 12/2021
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2021
1	Mental Disorders (Mental Disorder) 01/2021
1	Genetic Predisposition to Disease (Genetic Predisposition) 01/2021
1	Memory Disorders (Memory Loss) 10/2020
1	Alcoholism (Alcohol Abuse) 01/2020
1	Nausea 01/2020
1	Autism Spectrum Disorder 01/2020
1	Chronic Renal Insufficiency 10/2019
1	Sensorineural Hearing Loss 10/2018
1	Trichotillomania 01/2018
1	Treatment-Resistant Schizophrenia 03/2017
1	Cerebral Cortical Thinning 01/2017
1	Hallucinations (Hallucination) 01/2016
1	Stroke (Strokes) 01/2016
1	Mania (Manias) 06/2014

Drug/Important Bio-Agent (IBA)

24	7,7'- dimethoxy- (4,4'- bi- 1,3- benzodioxole)- 5,5'- dicarboxylic acid dimethyl ester (BDD)IBA 12/2021 - 08/2010
12	Silver Sulfadiazine (SSD)FDA LinkGeneric 12/2022 - 01/2019
5	Acetylcysteine (Siran)FDA LinkGeneric 01/2022 - 12/2015
5	Biological ProductsIBA 01/2022 - 01/2017
4	Ketamine FDA LinkGeneric 04/2015 - 02/2006
3	Clozapine (Clozaril)FDA LinkGeneric 01/2022 - 12/2015
3	Methamphetamine (Desoxyn)FDA LinkGeneric 12/2021 - 01/2019
3	Pharmaceutical PreparationsIBA 01/2020 - 08/2014
3	Antipsychotic Agents (Antipsychotics)IBA 03/2017 - 01/2014
2	Glutathione (Reduced Glutathione)IBA 01/2022 - 02/2020
2	AntioxidantsIBA 01/2022 - 02/2020
2	ElementsIBA 01/2022 - 01/2018
2	Indicators and Reagents (Reagents)IBA 12/2021 - 06/2014
2	Muscarinic Receptors (Muscarinic Acetylcholine Receptor)IBA 01/2019 - 10/2018
2	Muscarinic M1 ReceptorIBA 01/2019 - 10/2018
2	Cholinergic Agents (Cholinergics)IBA 10/2018 - 08/2015
2	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 04/2015 - 04/2009
1	Cysteine (L-Cysteine)FDA Link 01/2022
1	Biomarkers (Surrogate Marker)IBA 01/2022
1	norclozapineIBA 01/2022
1	Polytetrafluoroethylene (Teflon)FDA Link 03/2021
1	Triglycerides (Triacylglycerol)IBA 01/2021
1	Varenicline (Chantix)FDA Link 01/2020
1	Nicotinic Receptors (Nicotinic Acetylcholine Receptor)IBA 01/2020
1	Oxytocin (Pitocin)FDA LinkGeneric 01/2019
1	Dopamine Agonists (Dopamine Agonist)IBA 04/2015
1	antineoplaston A10 (A 10)IBA 12/2013
1	Selective Serotonin Reuptake Inhibitors (Serotonin Reuptake Inhibitors)IBA 01/2006

Therapy/Procedure

8	Therapeutics 01/2021 - 01/2016
1	Contraindications 12/2021
1	Transcranial Direct Current Stimulation 11/2019
1	Hearing Aids (Hearing Aid) 10/2018